Biolegend, 103147, Brilliant Violet 711™ anti-mouse CD45 Antibody, 50μg

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
Application References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Korsunsky I, et al. 2022. Med. 3:481. PubMed Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed Duhalde Vega M, et al. 2022. Sci Adv. 8:eabn6545. PubMed Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed Li L, et al. 2023. iScience. 26:106095. PubMed Park JA, et al. 2023. J Immunother Cancer. 11:. PubMed Liu SY, et al. 2023. STAR Protoc. 4:102240. PubMed Banka AL, et al. 2023. Nat Commun. 14:2462. PubMed Sefik E, et al. 2022. Nature. 606:585. PubMed Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed McAlpine CS, et al. 2022. J Exp Med. 219: . PubMed Klapproth E, et al. 2022. Nat Commun. 13:7648. PubMed Patton T, et al. 2023. Cell Death Dis. 14:111. PubMed Chen K, et al. 2022. Adv Sci (Weinh). 9:e2104106. PubMed Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed Qi Z, et al. 2022. Nat Commun. 13:182. PubMed Harel M, et al. 2020. Cell. 179(1):236-250.e18.. PubMed Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed Ayasoufi K, et al. 2020. Brain. 3629:143. PubMed Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Hole CR, et al. 2019. Nat Commun. 10:2955. PubMed Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed McAlpine CS, et al. 2021. Nature. 595:701. PubMed Stump CT, et al. 2021. Open Biol. 11:210245. PubMed Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed Xu S, et al. 2021. Immunity. . PubMed Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed Bachofner M, et al. 2017. Dev Cell. 42:616. PubMed Lewis EL, et al. 2021. Front Immunol. 12:741518. PubMed Cardenas JJ, et al. 2020. Methods Enzymol. 415:631. PubMed Sefik E, et al. 2021. Nat Biotechnol. . PubMed Zhang SL, et al. 2022. Gut Microbes. 14:2046246. PubMed Lin J, et al. 2021. Nat Commun. 12:5321. PubMed Beura LK, et al. 2018. Immunity. 48:327. PubMed Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed Wu S, et al. 2021. Nat Cancer. 2:189. PubMed Johann K, et al. 2021. Nat Commun. 12:5981. PubMed Ivan DC, et al. 2021. Front Immunol. 12:666961. PubMed Silva DA, et al. 2019. Nature. 565:186. PubMed Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed Ryu S, et al. 2021. eLife. 0.416666666666667. PubMed Tao Z, et al. 2022. Cells. 11:. PubMed Olivera GC, et al. 2021. Elife. 10:. PubMed Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed McGinley AM, et al. 2020. Immunity. 52(2):342-356. PubMed Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
RRID: AB_2564383 (BioLegend Cat. No. 103147)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45 on UniProt.org
Clone: 30-F11
Regulatory Status: RUO
Other Names: T200, Ly-5, LCA
Isotype: Rat IgG2b, κ